Regulatory Briefs: HHS Agenda; Cardiopulmonary Blood Pump Reclassification; FDA Meetings
This article was originally published in The Gray Sheet
Executive Summary
HHS issued a semiannual report detailing the regulatory agenda for FDA in 2014. FDA reclassifies cardiopulmonary bypass blood pumps. More regulatory news.
You may also be interested in...
Research Briefs: Edwards Starts New Sapien 3 Trial; Upper Airway Stimulator For Sleep Apnea
FDA has approved an investigational device exemption for Edwards Lifesciences’ trial of the Sapien 3 transcatheter aortic valve in intermediate-risk patients. The New England Journal of Medicine publishes results of the STAR trial of Inspire Medical’s upper airway stimulator for treatment of sleep apnea.
Obstructive Sleep Apnea: CPAP Under Pressure As New Market Segments Awaken
An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.
Science Board Investigates How FDA Has Responded To Critical 2007 Report
A subcommittee is evaluating progress the agency has made in regulatory science since the 2007 report, “FDA Science and Mission at Risk,” was issued, while identifying future needs.